Intellectual Property Magazine
Crunch time
Daniel Lim, Kirkland Ellis
In part one
1 of this two-part series on CRISPR,we considered some of the groundbreaking research conducted in 2019 and what wecan expect
to hear about in 2020, both in terms of basic science and thetranslational work being done to bring new CRISPR-based therapies
into theclinic.